A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs PBI 4050 (Primary)
- Indications Cystic fibrosis; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors ProMetic Life Sciences
- 28 Feb 2018 Status changed from recruiting to discontinued.
- 21 Feb 2017 Status changed from not yet recruiting to recruiting.
- 18 May 2016 According to ProMetic Life Sciences media release, company has received approval by Health Canada to commence this study.